TEIKA PHARMACEUTICAL CO., LTD.
|TEIKA PHARMACEUTICAL CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20100267665||REMEDY FOR CORNEAL DISEASES - The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.||10-21-2010|
|20100174247||EYE DROPS CONTAINER - An eye drops container including a container body filled with a drug solution along with a pressurized gas and including a valve mechanism discharging a fixed amount of drug solution; a nozzle member coupled with a stem for open operation of the valve mechanism and including a drug solution drop nozzle; an operating member including an operating piece and attached to the container body; a guide member contained in the operating member and guiding the nozzle member in the axial direction; and a ball contained in the guide member. The nozzle member includes an outer flange for suspending a skirt on the lower surface thereof; the guide member includes a ring-like bottom groove into which the forward end of the skirt enters; and the ball falls into the bottom groove in an upright state to block the open operation of the valve mechanism, and falls onto the outer flange in an inverted state to permit the open operation of the valve mechanism.||07-08-2010|
|20100120908||EYE DROP PREPARATION COMPRISING LATANOPROST - Disclosed is an eye drop preparation comprising latanoprost, which is characterized in that the degradation of latanoprost in water can be prevented, the adsorption of latanoprost onto a plastic container can be prevented, and therefore the decrease in the latanoprost content can be prevented satisfactorily. The eye drop preparation comprises an eye drop composition comprising the following components (A)-(B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant.||05-13-2010|
|20100113456||THERAPEUTIC AGENT FOR CORNEAL DISEASE - A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.||05-06-2010|
|20100074943||MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME - An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc. This transdermal absorption preparation comprises a medicinal composition for transdermal absorption in which an active ingredient selected from morphine and salts thereof is blended in such an amount as corresponding to the saturation solubility or more in an active ingredient-holding vehicle having fluidity at a temperature around the human skin surface temperature and at least a portion of the active ingredient is held in a crystalline form, characterized in that, in the case where a preparation obtained from the above-described medicinal composition for transdermal absorption is applied to the uninjured skin of the back of a white rabbit having been shaven with electrical clippers for 72 hours, the available amount of the active ingredient per single dose of the preparation is from 10 mg to 400 mg in terms of morphine base, and the plasma concentrations of the active ingredient 24 hours and 48 hours after the application of the preparation under the above-described conditions are each at least 40 ng/mL in terms of morphine base, and so on.||03-25-2010|
|20090317354||Composition for restoring damaged skin comprising a saccaride and povidone-iodine - The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.||12-24-2009|
|20090030001||THERAPEUTIC AGENT FOR CORNEAL DISEASE - A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.||01-29-2009|
Patent applications by TEIKA PHARMACEUTICAL CO., LTD.